Menu
Subscribe - Individual
Subscribe - Biotech Premium (Corporate)
Home
About Us
Subscribe
Subscribe Individual
Subscribe Biotech Premium (Corporate)
Premium Biotech Coverage
Current News
Special Features
Company Index
Index Table
Summit
19th Bioshares Biotech Summit
Summit History
Contact
Contact Us
Email Alerts
Categories
Categories
Actinogen (ACW)
Adalta (1AD)
Anteris Technologies (AVR)
Aroa Biosurgery (ARX)
Blinklab (BB1)
Blog
Botanix (BOT)
Chimeric Therapeutics (CHM)
Clever Culture Systems (CC5)
Clinuvel Pharmaceuticals (CUV)
Cogstate (CGS)
Dimerix (DXB)
Immuron (IMC)
Imugene (IMU)
Island Pharmaceuticals (ILA)
Neuren Pharmaceuticals (NEU)
Syntara (SNT) (previously Pharmaxis, PXS)
Uncategorized
November 3rd, 2023
Aroa Biosurgery – On track for Revenue of NZ$72 - NZ$75 Million
Read More
November 3rd, 2023
Neuren Pharmaceuticals – Strong DAYBUE Sales in September Quarter at US$67 million
Read More
October 10th, 2023
Acquisition Targets for Australian Biotech Sector (Cogstate)
Read More
October 10th, 2023
Major Validation Deal for Dimerix
Read More
October 3rd, 2023
Acquisition Targets for Australian Biotech Sector (Anteris Technologies)
Read More
October 3rd, 2023
Pharmaxis (Syntara) Sells off Mannitol Business
Read More
September 19th, 2023
Clinuvel Pharmaceuticals v. Nanosonics
Read More
September 19th, 2023
Polynovo v AROA Biosurgery
Read More
September 4th, 2023
Respiri Signs Three US Remote Patient Monitoring Contracts
Read More
September 4th, 2023
Disappointing Half Year Sales for Cogstate; Pipeline for New Contracts at All-time High Levels
Read More
September 4th, 2023
Imugene to Acquire Fourth Technology Platform
Read More
September 4th, 2023
Robust Growth Expected to Continue for Clinuvel Pharmaceuticals
Read More
August 11th, 2023
2023 Bioshares Biotech Summit Coverage (Imugene)
Read More
August 11th, 2023
Pharmaxis - Meaningful Impact on Bone Marrow in Myelofibrosis Study
Read More
August 11th, 2023
Respiri - Targeting Cashflow Positive in 2024
Read More
August 11th, 2023
Dimerix in Partnering Discussions, Interim Results out March 2024
Read More
July 21st, 2023
Neuren Pharmaceuticals Moves to Worldwide License for Trofinetide and NNZ-2591 with Acadia
Read More
June 6th, 2023
Mixed Results from Pharmaxis' Scar Treatment Study
Read More
June 6th, 2023
EBR Systems Achieves Positive Results in Pivotal Study
Read More
May 19th, 2023
Immuron Receives FDA Clearance for Third US Study
Read More
Pages
1
2
3
4
5
6
7
8
9
